These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 9575760)

  • 21. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
    Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical equivalence by design for generic drugs: modified-release products.
    Raw AS; Lionberger R; Yu LX
    Pharm Res; 2011 Jul; 28(7):1445-53. PubMed ID: 21387150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic drug device combination products: Regulatory and scientific considerations.
    Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
    Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generating Model Integrated Evidence for Generic Drug Development and Assessment.
    Zhao L; Kim MJ; Zhang L; Lionberger R
    Clin Pharmacol Ther; 2019 Feb; 105(2):338-349. PubMed ID: 30414386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
    Oner ZG; Michel SLJ; Polli JE
    Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
    Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
    AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
    Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.
    Chazin HD; Peters JR; Catterson DM; Osterhout JL; Forsyth LM; Lee JE; Kim EK; Feibus KB
    Ther Innov Regul Sci; 2019 Mar; 53(2):249-253. PubMed ID: 29742934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription drug product substitution decision support.
    Manolakis PG
    J Am Pharm Assoc (2003); 2007; 47(3):328-38. PubMed ID: 17510028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products.
    Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S
    Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.